They observed that a combination of JQ1 and MEK inhibitors induced cytostasis and triggered apoptosis in tumor cells with obvious implications for clinical use of this combination therapy to treat NRAS‐mutant melanoma with higher levels of BRD4 that are resistant to MAPK inhibitors (Echevarría‐Vargas et al, 2018). Here, BRD4 is linked to neoplasm.